Ultragenyx Pharmaceutical/$RARE
Ultragenyx Pharmaceutical shares are trading lower after its brittle bone disease drug did not meet early study goals.
4 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Ticker
$RARE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,294
ISIN
US90400D1081
Website
RARE Metrics
BasicAdvanced
$3.9B
-
-$5.88
0.24
-
Price and volume
Market cap
$3.9B
Beta
0.24
52-week high
$58.73
52-week low
$29.59
Average daily volume
1.2M
Financial strength
Current ratio
2.397
Quick ratio
2.048
Long term debt to equity
543.374
Total debt to equity
346.939
Interest coverage (TTM)
-8.35%
Profitability
EBITDA (TTM)
-477.877
Gross margin (TTM)
-30.87%
Net profit margin (TTM)
-93.04%
Operating margin (TTM)
-86.94%
Effective tax rate (TTM)
-0.45%
Revenue per employee (TTM)
$460,000
Management effectiveness
Return on assets (TTM)
-24.51%
Return on equity (TTM)
-377.06%
Valuation
Price to revenue (TTM)
6.562
Price to book
26.93
Price to tangible book (TTM)
-50.66
Price to free cash flow (TTM)
-9.385
Free cash flow yield (TTM)
-10.66%
Free cash flow per share (TTM)
-441.57%
Growth
Revenue change (TTM)
33.46%
Earnings per share change (TTM)
-26.22%
3-year revenue growth (CAGR)
21.18%
3-year earnings per share growth (CAGR)
-5.10%
10-year earnings per share growth (CAGR)
10.73%
What the Analysts think about RARE
Analyst ratings (Buy, Hold, Sell) for Ultragenyx Pharmaceutical stock.
RARE Financial Performance
Revenues and expenses
RARE Earnings Performance
Company profitability
RARE News
AllArticlesVideos
Ultragenyx shares plunge after bone disorder trial misses key interim goal
Proactive Investors·2 hours ago
Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win
Benzinga·7 hours ago
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga·9 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ultragenyx Pharmaceutical stock?
Ultragenyx Pharmaceutical (RARE) has a market cap of $3.9B as of July 10, 2025.
What is the P/E ratio for Ultragenyx Pharmaceutical stock?
The price to earnings (P/E) ratio for Ultragenyx Pharmaceutical (RARE) stock is 0 as of July 10, 2025.
Does Ultragenyx Pharmaceutical stock pay dividends?
No, Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next Ultragenyx Pharmaceutical dividend payment date?
Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders.
What is the beta indicator for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) has a beta rating of 0.24. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.